Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
62.1 USD | -3.00% | -4.86% | -25.62% |
May. 09 | Oppenheimer Adjusts Cytokinetics Price Target to $106 From $107, Maintains Outperform Rating | MT |
May. 08 | Cytokinetics Q1 Net Loss Narrows, Revenue Declines | MT |
Financials (USD)
Sales 2024 * | 13.9M | Sales 2025 * | 95.36M | Capitalization | 6.51B |
---|---|---|---|---|---|
Net income 2024 * | -496M | Net income 2025 * | -461M | EV / Sales 2024 * | 466 x |
Net cash position 2024 * | 33.92M | Net cash position 2025 * | 530M | EV / Sales 2025 * | 62.7 x |
P/E ratio 2024 * |
-13
x | P/E ratio 2025 * |
-15.1
x | Employees | 423 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.42% |
Latest transcript on Cytokinetics, Incorporated
1 day | -3.00% | ||
1 week | -4.86% | ||
Current month | +1.27% | ||
1 month | -16.49% | ||
3 months | -19.29% | ||
6 months | +91.08% | ||
Current year | -25.62% |
Managers | Title | Age | Since |
---|---|---|---|
Robert Blum
CEO | Chief Executive Officer | 60 | 98-06-30 |
Kari Loeser
CMP | Compliance Officer | - | 21-10-31 |
Stuart Kupfer
CTO | Chief Tech/Sci/R&D Officer | - | 19-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Nancy Wysenski
BRD | Director/Board Member | 66 | 20-11-19 |
Edward Kaye
BRD | Director/Board Member | 74 | 16-05-19 |
Santo Costa
BRD | Director/Board Member | 78 | 10-09-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.44% | 0 M€ | 0.00% | - | |
0.39% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-10 | 62.1 | -3.00% | 1,343,709 |
24-05-09 | 64.02 | -1.92% | 2,404,751 |
24-05-08 | 65.27 | -0.02% | 1,174,612 |
24-05-07 | 65.28 | +0.35% | 849,388 |
24-05-06 | 65.05 | -0.34% | 607,007 |
Delayed Quote Nasdaq, May 10, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-25.62% | 6.71B | |
+3.91% | 108B | |
+10.87% | 104B | |
+1.28% | 22.33B | |
-13.14% | 22.19B | |
-7.05% | 18.69B | |
-38.36% | 17.74B | |
-10.66% | 17.64B | |
+3.75% | 14.05B | |
+36.70% | 12.51B |
- Stock Market
- Equities
- CYTK Stock